Soleno Therapeutics (SLNO) Gains from Investment Securities: 2013-2024
Historic Gains from Investment Securities for Soleno Therapeutics (SLNO) over the last 12 years, with Dec 2024 value amounting to $2.8 million.
- Soleno Therapeutics' Gains from Investment Securities rose 481.17% to $7.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was $7.0 million, marking a year-over-year increase of 360.89%. This contributed to the annual value of $2.8 million for FY2024, which is 374.87% up from last year.
- Latest data reveals that Soleno Therapeutics reported Gains from Investment Securities of $2.8 million as of FY2024, which was up 374.87% from $597,000 recorded in FY2023.
- In the past 5 years, Soleno Therapeutics' Gains from Investment Securities ranged from a high of $2.8 million in FY2024 and a low of -$11.6 million during FY2020.
- In the last 3 years, Soleno Therapeutics' Gains from Investment Securities had a median value of $597,000 in 2023 and averaged $1.1 million.
- As far as peak fluctuations go, Soleno Therapeutics' Gains from Investment Securities plummeted by 267.10% in 2020, and later spiked by 2,090.00% in 2023.
- Yearly analysis of 5 years shows Soleno Therapeutics' Gains from Investment Securities stood at -$11.6 million in 2020, then skyrocketed by 104.99% to $581,000 in 2021, then plummeted by 105.16% to -$30,000 in 2022, then spiked by 2,090.00% to $597,000 in 2023, then surged by 374.87% to $2.8 million in 2024.